|Trade names||Nurtec ODT, Vydura|
|Other names||BHV-3000, BMS-927711|
|Drug class||calcitonin gene-related peptide receptor antagonist|
|CompTox Dashboard (EPA)|
|Chemical and physical data|
|Molar mass||534.568 g·mol−1|
|3D model (JSmol)|
Rimegepant, sold under the brand name Nurtec ODT among others, is a medication for the acute treatment of migraine with or without aura in adults and preventative treatment of episodic migraine in adults.
Taken by mouth to dissolve on or under the tongue, rimegepant takes effect within an hour and can provide relief from migraine headache for up to 48 hours. It works by blocking CGRP receptors.
In the United States, rimegepant was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021. It is produced and marketed by Biohaven Pharmaceuticals, based in New Haven, Connecticut. During March 2021, Nurtec ODT obtained approval from the United Arab Emirates and Israel.
Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.
Originally discovered at Bristol-Myers Squibb, rimegepant was developed by Biohaven Pharmaceuticals, which markets the drug in the United States after receiving FDA approval in February 2020. Approval was based on evidence from one clinical trial of 1,351 subjects with migraine headaches.
On 24 February 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Vydura, intended for the prophylaxis and acute treatment of migraine. The applicant for this medicinal product is Biohaven Pharmaceutical Ireland DAC. Rimegepant was approved for medical use in the European Union in April 2022.
((cite web)): CS1 maint: url-status (link)